Yazar "Arpaci, Nazile" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Neonatal outcomes in pregnant women with untreated and treated panic disorder(W B Saunders Co-Elsevier Inc, 2018) Uguz, Faruk; Yuksel, Goksen; Onur, Ozge Sahmelikoglu; Karsidag, Cagatay; Gezginc, Kazim; Arpaci, NazileObjective: The objective of the present study was to compare neonatal outcomes including gestational age, birth weight and hospitalization of newborns of pregnant women with treated with antidepressants and untreated panic disorder. Methods: The study sample included 146 pregnant women (44 patients with panic disorder treated with antidepressants, 52 patients with untreated panic disorder, and 50 healthy controls). Panic disorder was diagnosed by means of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Results: The highest proportions of preterm birth (28.8%), low birth weight (34.6%) and requirement of neonatal care (25.0%) were observed in infants of untreated patients. Pharmacotherapy group and control subjects had similar neonatal outcomes. Compared with infants of healthy subjects and the pharmacotherapy group, infants of untreated patients had significantly lower birth weight and gestational age at delivery. In addition, newborns of untreated patients had higher rate of hospitalization at the neonatal care unit. Conclusion: Our results suggest that treatment with pharmacotherapy of panic disorder during pregnancy may have beneficial effects on the risk of negative neonatal outcomes due to maternal panic disorder in the infants. (C) 2018 Elsevier Inc. All rights reserved.Öğe The Role of the Central and the Peripheral Neuropeptides in Weight Gain and Metabolic Changes Related to Olanzapine(Aves, 2021) Arpaci, Nazile; Ak, Mehmet; Uguz, Faruk; Kurban, Sevil; Kulaksizoglu, SevsenObjective: This study aimed to examine the role of central and peripheral neuropeptides in olanzapine-induced weight gain and metabolic changes. Materials and Methods: Thirty patients who would receive olanzapine treatment were evaluated at the beginning of the treatment at the 2nd and 8th weeks. Weight, waist circumference, the central neuropeptides pro-opiomelanocortin (POMC) and neuropeptide Y (NPY), and the peripheral adipokine leptin and the peripheral peptide cholecystokinin (CCK) levels were measured in each control. In addition, biochemical parameters such as fasting blood glucose (FBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total and direct bilirubin, very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol, and triglyceride (TG) were measured. Results: There were statistically significant differences weight and waist circumference levels compared to the initial levels. As observed in previous studies in the literature, changes in biochemical parameters including AST, ALT, total and direct bilirubin, LDL, TG, total cholesterol, and HDL levels were statistically significant. Levels of the neuropeptides POMC and NPY tended to increase at early stages and decrease at later stages of the treatment, while CCK and leptin levels kept increasing throughout the treatment period. The changes in POMC and CCK levels were statistically significant. Conclusion: The results suggest that POMC and CCK may play a role in olanzapine-related weight gain.Öğe Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital(Mary Ann Liebert, Inc, 2016) Uguz, Faruk; Arpaci, NazileObjective: Primary pharmacological agents for depression and anxiety disorders are antidepressants, especially selective serotonine reuptake inhibitors. The aim of this study was to examine the features and prevalence of adverse effects of paroxetine and sertraline in breastfed infants. Methods: The study had a retrospective cohort design. Five-year clinical data of 72 patients were included in the study. Psychiatric diagnoses were ascertained by means of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Results: The prevalence rate of adverse events in the infants was 12.5%. Insomnia (88.9%), restlessness (55.6%), and constant crying (22.2%) were the most frequent adverse events. A switch between paroxetine and sertraline performed in five patients, who reported an adverse event in their breastfed infants, resulted in cessation of the adverse events. Conclusion: The results suggest that the prevalence rate of adverse events in the infants exposed to sertraline or paroxetine is relatively low and mostly mild.Öğe Weight Gain and Metabolic Changes Due to Olanzapine Treatment in Psychotic Patients(Karger, 2018) Arpaci, Nazile; Ak, Mehmet; Subasi, Elif; Uguz, Faruk; Koca, Raviye Ozen; Kutlu, Selim[Abstract Not Availabe]
